In patients with intrahepatic cholangiocarcinoma (iCCA) enrolled in the FIGHT-202 trial11, pemigatinib did not result in a favourable response in the group with FGFR2 mutations. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.